Repatha and Basaglar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repatha (evolocumab) and Basaglar (insulin glargine). Common drug interactions include hospitalisation among females and infection among males.

The phase IV clinical study analyzes what interactions people have when they take Repatha and Basaglar. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Basaglar?

Basaglar has active ingredients of insulin glargine. eHealthMe is studying from 19,807 Basaglar users. Check the latest studies of Basaglar.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

31 people who take Repatha and Basaglar together, and have interactions are studied.

What are the common drug interactions of Repatha and Basaglar, by gender? *:

female:

Hospitalisation
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Nausea (feeling of having an urge to vomit)
Asthenia (weakness)
Blood glucose increased
White blood cell count decreased
Drug ineffective
Kidney infection
Loss of consciousness
Low density lipoprotein increased (cholesterol increased in blood)

male:

Infection
Death
Dyspnoea (difficult or laboured respiration)
Injection site mass
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Pain
Pneumonia
Vomiting

What are the common drug interactions of Repatha and Basaglar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Drug ineffective
Low density lipoprotein increased (cholesterol increased in blood)
Blood glucose increased

40-49:

Fatigue (feeling of tiredness)
Amputation
Asthenia (weakness)
Colostomy
Confusional state
Flushing (the warm, red condition of human skin)
Groin pain
Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery)
Malaise (a feeling of general discomfort or uneasiness)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

50-59:

Hospitalisation

60+:

Nausea (feeling of having an urge to vomit)
Fall
Fatigue (feeling of tiredness)
Glycosylated haemoglobin increased
Injection site mass
Malignant neoplasm progression (cancer tumour came back)
Neoplasm malignant (cancer tumour)
Pain
Pancreatitis (inflammation of pancreas)
Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)

What are the existing conditions these people have? *

Type 2 Diabetes: 3 people, 9.68%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 9.68%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 6.45%
Low Density Lipoprotein Increased (cholesterol increased in blood): 2 people, 6.45%
Diabetes: 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and Basaglar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously